Hint mode is switched on Switch off

Poseida Therapeutics, ordinary share
PSTX, US73730P1084

Add a stock to WL
Choose all Reset all
Poseida Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Issuer

Profile
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging its proprietary next-generation, non-viral gene engineering technologies to create life-saving cell therapeutics for patients with high unmet medical need.
  • Issuer
  • Full borrower / issuer name
    Poseida Therapeutics Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    PSTX
  • Placement
    10.07.2020
  • Lock up period
    180
  • Number of papers
    14,000,000
  • Volume of raised funds
    224 mln USD
  • Placement share
    22.65%
  • Final placement price
    16 USD
  • Price change since placement date
    -100%
  • By capitalization
    989.05 mln USD
Other placements of the issuer
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    PSTX
  • Placement
    04.08.2022
  • Lock up period
    180
  • Number of papers
    20,000,000
  • Volume of raised funds
    70 mln USD
  • Placement share
    24.18%
  • Final placement price
    3.5 USD
  • Price change since placement date
    -100%
  • By capitalization
    289.55 mln USD

IFRS/US GAAP reports

2024
I q eng
II q eng
III q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
II q eng
III q eng
IV q eng
Show all Hide

Indicators

News

07/11/2024 Poseida Therapeutics: Results Of Operations And Financial Condition, Financial Statements And Exhibits
27/09/2024 Poseida Therapeutics: Other Events
30/04/2024 Poseida Therapeutics: Of This Report (including Exhibit 99.1) Is Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended. The Information Shall Not Be Deemed Incorporated By Reference Into Any Other Filing With The Securities And Exchange Commission Made By The Company, Whether Made Before Or After Today S Date, Regardless Of Any General Incorporation Language In Such Filing, Except As Shall Be Expressly Set Forth By Specific References In Such Filing, Financial Statements And Exhibits
17/04/2024 Poseida Therapeutics: Of This Report (including Exhibits 99.1 And 99.2) Is Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended. The Information Shall Not Be Deemed Incorporated By Reference Into Any Other Filing With The Securities And Exchange Commission Made By The Company, Whether Made Before Or After Today S Date, Regardless Of Any General Incorporation Language In Such Filing, Except As Shall Be Expressly Set Forth By Specific References In Such Filing, Financial Statements And Exhibits
08/04/2024 Poseida Therapeutics: Of This Report (including Exhibit 99.1, Exhibit 99.2 And Exhibit 99.3) Is Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended. The Information Shall Not Be Deemed Incorporated By Reference Into Any Other Filing With The Securities And Exchange Commission Made By The Company, Whether Made Before Or After Today S Date, Regardless Of Any General Incorporation Language In Such Filing, Except As Shall Be Expressly Set Forth By Specific References In Such Filing, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.